(Q37463877)

20 August 2017

1 reference

title

Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein (English)

1 reference

20 August 2017

1 reference

1

William G Kaelin

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

issue

10 Suppl

1 reference

20 August 2017

page(s)

2262-2272

1 reference

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

Cystic kidney diseases: all roads lead to the cilium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Molecular basis of the VHL hereditary cancer syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Von Hippel-Lindau disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an ind

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The primary cilium as the cell's antenna: signaling at a sensory organelle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Role of primary cilia in the pathogenesis of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Primary cilium formation requires von hippel-lindau gene function in renal-derived cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

pVHL and GSK3beta are components of a primary cilium-maintenance signalling network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

VEGF signalling: integration and multi-tasking in endothelial cell biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The Akt-mTOR tango and its relevance to cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Hsp90: a novel target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

The concept of synthetic lethality in the context of anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24232

7 January 2021

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/CNCR.24232

Identifiers

DOI

10.1002/CNCR.24232

1 reference

20 August 2017

1 reference